Valuation check: CDXC's profit margin is Infinity%, above the Healthcare sector average of 15.52%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
As of the most recent data (March 2026), CDXC shows a profit margin of Infinity%. That compares with 16.25% in the prior-year period — up Infinity% year over year. That is above the Healthcare sector average of 15.52%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CDXC's profit margin is now Infinity% (was 16.25%) — a Infinity% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Chromadex is outperforming or lagging.
The Healthcare sector average profit margin is about 15.52%. Chromadex is at Infinity%, which is higher that average. That is roughly Infinity% above the sector mean. Use the comparison chart on this page to see how CDXC stacks up against individual peers as well.
That compares with 16.25% in the prior-year period — up Infinity% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Chromadex with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Chromadex's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently Infinity%) with ownership activity and broader fundamentals.